Tumor cells exhibit high levels of gly colysis despite the presence of ample oxygen, a phenomenon termed aero bic glycolysis. This observation was first published by Warburg et al. (1924) ; it has since been supported by multiple studies in a variety of tumor types, and is now exploited in the clinic for diagnostic purposes. Positron emission tomography using 2deoxy2( 18 F) fluoroDglucose, a glucose analogue, demonstrates a significant increase in glucose uptake in tumors compared with adjacent normal tissue (Gambhir, 2002 ). Warburg's initial observations led him to hypothesize that cancer is caused by mitochondrial injury, followed by an increase in glycolysis that converts differentiated cells into proliferating cancer cells (Warburg, 1956) . However, primary defects in mitochondrial en zymes or complexes within the elec tron transport chain are not frequently observed in cancer (Frezza and Gottlieb, 2009) . Recent studies indicate that the activation of protooncogenes (e.g., Myc), signaling pathways (e.g., PI3K), and transcription factors (e.g., HIF1), as well as the inactivation of tumor suppressors (e.g., p53), induce the War burg effect in cancer cells Glycolysis generates ATP with lower efficiency, but at a faster rate, than oxidative phosphorylation (Pfeiffer et al., 2001 ). This enhanced rate of ATP gen eration has been postulated to be bene ficial for rapidly proliferating cells. However, this is probably not the main reason why proliferating cells engage in high levels of aerobic glycolysis, as multiple studies have suggested that mitochondria are the major source of cellular ATP in most cancer cell lines and tissues (Zu and Guppy, 2004) . Fur thermore, it was recognized >30 yr ago that galactose or fructose, which are preferentially shunted into glycolytic subsidiary pathways and do not gener ate substantial amounts of glycolytic ATP, allow cancer cells to proliferate in the absence of glucose (Reitzer et al., 1979) . Thus, high glycolytic rates likely benefit proliferating cells through the production of glycolytic intermediates, which are shunted into subsidiary path ways to fuel metabolic pathways that generate de novo nucleotides, lipids, amino acids, and NADPH (Lunt and Vander Heiden, 2011) .
Meeting the biosynthesis needs of proliferating cells
Glycolytic intermediates fuel several biosynthetic pathways that are essential for duplication of biomass during cel lular proliferation (Fig. 1) . After cellular uptake through glucose transporters (GLUTs), glucose is phosphorylated by hexokinases (HKs), which pro duces glucose6phosphate. Glucose 6phosphate can either proceed into glycolysis through conversion into fructose6phosphate by glucose6 phosphate isomerase, or it can be shunted into the oxidative branch of the pentose phosphate pathway (PPP) by glucose6phosphate dehydroge nase. The oxidative branch of the PPP generates NADPH, which is used for the reduction of cellular glutathione pools to promote redox homeostasis and acts as a reducing agent for lipid, nucleotide, and amino acid biosyn thesis. The nonoxidative branch of the PPP generates ribose5phosphate, which is used in the biosynthesis of nucleic acids. Back in glycolysis, phos phofructokinase1 (PFK1) irrevers ibly converts fructose6phosphate to fructose1,6bisphosphate. Fructose 1,6bisphosphate is converted into glyceraldehyde3phosphate or dihy droxyacetone phosphate. The latter is a precursor to glycerol3phosphate, which is crucial for the biosynthesis of the phospholipids and triacylglyc erols required for generation of cell membranes. Fructose6phosphate and glyceraldehyde3phosphate can also combine to generate ribose5 phosphate through transketolases and transaldolases. Further down the gly colytic pathway, 3phosphoglycerate can undergo oxidation to generate serine and NADH. Serine can be used to generate two critical amino acids, cysteine and glycine, and to generate important signaling molecules such as ceramide.
Cellular transformation is associated with the reprogramming of cellular pathways that control proliferation, survival, and metabolism. Among the metabolic changes exhibited by tumor cells is an increase in glucose metabolism and glucose dependence. It has been hypothesized that targeting glucose metabolism may provide a selective mechanism by which to kill cancer cells. In this minireview, we discuss the benefits that high levels of glycolysis provide for tumor cells, as well as several key enzymes required by cancer cells to maintain this high level of glucose metabolism. It is anticipated that understanding which metabolic enzymes are particularly critical for tumor cell proliferation and survival will identify novel therapeutic targets. 6bisphosphate (Spoden et al., 2009) . PKM2 is phosphorylated on tyrosine 105 downstream of growth factor signaling, disrupting tetramer assembly required for PKM2 activity (Hitosugi et al., 2009 ). Furthermore, high glucose consumption triggers acetylation of PKM2 at lysine 305 to further reduce its activity (Lv et al., 2011) . This inhibition of PKM2 allows diversion of glycolytic intermediates up stream of pyruvate into biosynthetic pathways. Under these conditions, PEP can be converted to pyruvate through alternative, non-ATPproducing path ways, allowing for lactate and NAD + generation (Vander Heiden et al., 2010) .
Targets for cancer therapy
Targeting metabolic pathways for can cer therapy seems appealing at first glance, as enzymes are attractive mo lecular targets. However, to be an at tractive candidate for cancer therapy, there must be a significant difference in the requirement for a given enzyme's activity between cancer cells and nor mal proliferating cells. A few potential candidates that are overexpressed in certain cancer types include GLUT1, HKII, phosphoglycerate dehydrogenase (PHGDH), and LDHA (Fig. 1) .
GLUT1 is overexpressed in many cancer types, including renal cell carci nomas (RCCs) that exhibit loss of the von HippelLindau (VHL) tumor sup pressor gene (Younes et al., 1996; Chan et al., 2011) . A recent study identi fied a series of small molecules that inhibit GLUT1 and selectively kill VHL deficient RCCs (Chan et al., 2011) .
HKs catalyze the first step of glycoly sis and are another potentially attractive target. There are four mammalian HKs (HKI-IV). HKI is the ubiquitously ex pressed isoform, whereas HKII is ex pressed in insulinsensitive tissues such as muscle and adipose (Robey and Hay, 2006) . Many tumor cells overexpress HKII, and preclinical studies demonstrate that HKII inhibition could be an effective cancer therapy (Jae et al., 2009) .
PHGDH converts 3phosphoglyc erate into 3phosphohydroxypyruvate, a ratelimiting step in the conversion of 3phosphoglycerate into serine. Two re cent studies reported that subsets of Although NAD + can also be regenerated by mitochondria, this requires the trans port of NADH into the mitochondria through various shuttles that are likely too slow to meet the high demands of the cytosolic NAD + required to maintain glycolysis (Locasale and Cantley, 2011) .
Emerging studies indicate that py ruvate kinase (PK) plays an essential role in regulating the balance between glycolytic ATP generation and bio synthetic needs for proliferating cells (Christofk et al., 2008b) . PK catalyzes the ratelimiting and ATPproducing step of glycolysis in which phosphoenol pyruvate (PEP) is converted to pyru vate. Cancer cells express higher levels of M2 isoform (PKM2) over the more catalytically active M1 isoform (PKM1), and cancer cells engineered to express PKM1 instead of PKM2 exhibit re duced tumorforming ability (Christofk et al., 2008a; Bluemlein et al., 2011) . PKM2 alternates between a dimer that exhibits low catalytic activity and a highly active tetramer that is driven by allosteric binding of fructose1,
Mechanisms maintaining high glycolytic flux
Cellular glycolytic rates are subject to several negative feedback mechanisms, which proliferating cells must overcome to maintain biosynthesis. PFK1 is a critical driver of glycolytic flux and is allosterically inhibited by high ATP levels. Proliferating cells upregulate the expression of PFK2, which gener ates fructose2,6bisphospate, a potent allosteric activator of PFK1, thus main taining high glycolytic flux in the pres ence of high ATP (Vora et al., 1985; Colombo et al., 2010) . High glycolytic flux is also maintained by the overex pression of lactate dehydrogenase (LDH), a transcriptional target of Myc (Shim et al., 1997) . LDH generates NAD + from NADH while reducing pyruvate to lactate. NAD + regeneration is necessary for continued flux through glycolysis, as NAD + is required for conversion of glyceraldehyde3phosphate to 1,3 bisphosphoglycerate. The overexpres sion of LDH is sufficient to increase glycolytic flux (Shim et al., 1997) . PKM2 inhibition by siRNA selectively induces caspasedependent cell death, suggesting that PKM2 might regulate apoptosis through yet to be defined mechanisms. Interestingly, PKM2 has recently been shown to bind to and en hance the transcriptional activity of the hypoxiainducible factor1 (HIF1; Luo et al., 2011) . HIF1 is a critical mediator of cellular adaptation to hy poxic stress through transcription of diverse targets including GLUTs and glycolytic enzymes such as HKII and LDHA. It will be important to deter mine whether pharmacological inhibi tion of PKM2 can inhibit HIF1 transcriptional activity or whether inhi bition of PKM2 expression is required. Similarly, PKM2 has been show to as sociate with OCT4 and catenin, two transcription factors associated with tumor progression (Lee et al., 2008; Yang et al., 2011) . Going forward, it will be important to decipher whether PKM2 inhibition or activation affects nongly colytic functions of PKM2, and whether PKM2 interaction with nonglycolytic proteins is important for tumorigenesis.
Conclusions and future directions
The genetic revolution brought with it the discovery of genes and signaling path ways that promote or repress cellular transformation, and a genetic basis for un derstanding tumorigenesis. More recent work has focused on deciphering inter actions between these proliferative path ways and cellular metabolic pathways. Currently, there are three major issues that need to be addressed to determine whether targeting glucose metabolism is a viable strategy for cancer therapy.
First, to date, the genetic or pharma cologic interventions performed have primarily been done using human can cer cells injected subcutaneously into nude mice. It will be important for fu ture experiments to make use of geneti cally engineered mouse cancer models or orthotopic models with human can cer cells to assess whether glucose dependent pathways are promising targets for cancer therapy.
Second, the toxic effects of inhibit ing metabolic enzymes in normal cells need to be deciphered. Aside from cancer delivery of siRNA molecules target ing PKM2 causes tumor regression in mouse xenograft models. This is poten tially promising, as recent advances in nanotechnology are attempting to target siRNA delivery specifically to tumor cells in vivo.
Although seemingly irreconcilable with the data from Anastasiou et al., 2011 , these disparate results may be ex plained by cellular responses to varying degrees of hypoxia. Moderate hypoxia (1.5% O 2 ) promotes mitochondrial gen eration of hydrogen peroxide (H 2 O 2 ), which activates signaling pathways criti cal for the cellular response to hypoxia. Under these conditions, PKM2 be comes oxidized, which inhibits its activ ity, promotes flux through the PPP, and promotes redox balance (Anastasiou et al., 2011) . This prevents accumulation of aberrantly high levels of cellular H 2 O 2 and oxidative cellular damage. Under severe hypoxia (<0.5% O 2 ), however, oxygen becomes limiting for the mito chondrial electron transport chain and production of mitochondrial ATP and H 2 O 2 ceases. Under these conditions, cells become dependent on PK activity for ATP production. Thus, PKM2 in hibitors and activators could both be therapeutically beneficial for different reasons. PKM2 inhibitors would pre vent ATP production in severely hy poxic cells, whereas PKM2 activators would promote oxidative damage in moderately hypoxic cells. As most tumors exhibit a range of oxygen con centrations depending on tumor size and vascularization, whether PKM2 activa tion or inhibition is most therapeuti cally effective may be tumordependent. It is important to note that insufficient inhibition of PKM2 activity, which allows for glycolytic ATP production during severe hypoxia, would promote flux through biosynthetic pathways and possibly accelerate tumor growth. It will also be important to study the effects of PKM2 modulation in relatively well oxygenated tissues, such as the lung.
Another mechanism by which PKM2 inhibition by siRNA could potentially diminish tumor growth is by inhibiting other nonglycolytic functions of PKM2. Goldberg and Sharp (2012) posit that human melanoma and breast cancers have high levels of PHGDH, and these cancer cells are dependent on these en zymes for growth Possemato et al., 2011) .
LDHA was the first metabolic target demonstrated to be directly regulated by an oncogene (MYC), and genetic or pharmacologic inhibition of LDHA diminishes MYCdependent tumors (Shim et al., 1997; Le et al., 2010) . Although these are promising prelimi nary studies, GLUT1, HKII, PHGDH, and LDHA are expressed in normal tissues, and it remains to be seen whether inhibition of these enzymes will be effective in diminishing tumors with out imparting significant toxicity to normal tissues.
The finding that PKM2 expression provides a proliferative advantage for cancer cells raised the possibility that PKM2 could be an attractive target for cancer therapy. Tumors express higher levels of PKM2 than normal control tis sues (Bluemlein et al., 2011) ; however, inhibiting PKM2 could also allow gly colytic intermediates to accumulate and feed biosynthetic pathways, resulting in tumor promotion. Remarkably, there is data to suggest that either inhibiting or activating PKM2 in cancer cells dimin ishes tumor growth. Anastasiou et al. (2011) have recently demonstrated that PKM2 is regulated by cellular oxidative stress. PKM2 is specifically oxidized on cysteine 358, inhibiting its activity and promoting diversion of glycolytic in termediates into the PPP, producing NADPH and promoting redox balance. Expression of a nonoxidizable PKM2 mutant reduced flux through the PPP, increased oxidative stress, and inhibited tumor growth (Anastasiou et al., 2011) . These results indicate that PKM2 acti vators could be viable cancer therapeu tics, especially when used in conjunction with radiation or chemotherapeutic agents known to promote oxidative stress. Paradoxically, in this issue Goldberg and Sharp have demonstrated that inhibi tion of PKM2 activity using small in terfereing RNA (siRNA) increases apoptosis in cell culture, and can also inhibit tumor cell growth. Work by this group demonstrates that in vivo cells, immune cells and stem cells also display aerobic glycolysis. Unless anti metabolic therapies can distinguish be tween malignant and nonmalignant cells with selfrenewal capacity, then thera peutically targeting metabolism could be complicated by the same types of toxicity that plague conventional cyto toxic chemotherapeutic regimens.
Third, cancer cells display meta bolic plasticity. Thus, it is conceivable that cancer cells could develop resis tance to inhibition of a particular met abolic pathway through expression of alternate isoforms or upregulation of alternate pathways, such as gluconeo genesis. Adjacent cells such as adipo cytes may also provide precursors for the biosynthetic needs of tumor cells (Nieman et al., 2011) . Still, these are exciting times for the metabolism field as the links between gene expression, epigenetics, cell proliferation, differen tiation, and metabolic pathways are being uncovered.
